eters below the brain's surface. Unlike ECT for depression, rTMS does not
require anesthesia or analgesics."
Study subjects were antidepressant-free for one week prior to rTMS and
received 10 daily treatments (10 trains of five seconds each, 25 seconds apart)
at a frequency of 10 Hz. Seventy-eight percent of patients experienced
mild-moderate discomfort at the site of stimulation, two patients who
experienced severe pain in the treatment site dropped out of the study and eight
percent of patients experienced a posttreatment headache.
The mean age of patients treated was 52 years. " rTMS seems most
promising for older adults and for treatment-resistant patients with
depression," says Dr. McDonald, who directs the Fuqua Center for Late-Life
Depression at Wesley Woods.
Also collarborating on the study were Charles M. Epstein, M.D.,
associate professor of neurology at Emory; Liquong He, M.D., formerly with
Autumn L. Clark, B.S., study coordinator in Emory's department of psychiatry
and behavioral sciences; Fred A. Marstellar, Ph.D., associate professor of
and behavioral sciences at Emory; and John Woodard, Ph.D., of the Georgia State
University Memory Assessment Clinic.
The study was supported by a private grant from the Fuqua Foundation.
Page: 1 2 Related medicine news :1
Contact: Sarah Goodwin
Emory University Health Sciences Center
. Heart transplant survival: Results may be key to rejection prevention, detection, treatment2
. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial3
. Results from first clinical trial using GVG to treat addiction4
. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)5
. Media Advisory-- Results of California autism epidemiology study to be unveiled6
. Results of Yale study confirm aspirin helpful in preventing a first heart attack7
. Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions8
. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders9
. Results of NUVANCE phase I/II asthma trial presented10
. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia11
. UI Study Yields Encouraging Results For New Breast Cancer Treatment